BioRestorative Therapies raises $1.085M in registered direct offering at $1.60/share; warrants at $2.75

BioRestorative Therapies, Inc.

Registered direct offering of 678,125 shares at $1.60/share, gross proceeds $1.085M; closing expected Oct 8, 2025.
Concurrent private placement of warrants for 508,594 shares at $2.75 exercise price, 75% warrant coverage, exercisable after 6 months for 5 years.
Offering priced at $1.60/share, above October 3 close of $1.50.
Net proceeds to fund BRTX-100 clinical trials, ThermoStem R&D, biocosmeceuticals platform, and working capital.
CEO notes participation from largest institutional shareholder and management team.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

BioRestorative Therapies, Inc. issued up to an aggregate of 508,592 shares of the Company's common stock of warrant to several investors.

Security: warrant
Shares: up to an aggregate of 508,592 shares of the Company's common stock
Purchaser: several investors

Exact text from the filing

the Company agreed to issue to the Purchasers unregistered warrants (the “Unregistered Warrants”) to purchase up to an aggregate of 508,592 shares of the Company’s common stock (the “Unregistered Warrant Shares”) at an exercise price of $2.75 per share.

View on SEC.gov

Browse all equity issuances →

BioRestorative Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-017446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.